Study of nerve function in bladder cancer treatment
Part of Cancer clinical trials.
This trial looks at how a new treatment for advanced bladder cancer, called enfortumab vedotin, might affect your nerves. It aims to understand any nerve-related side effects so doctors can better manage them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years old or older.
- You have been diagnosed with urothelial carcinoma, a type of bladder cancer.
- Your cancer is locally advanced or has spread to other parts of the body.
- You are planning to receive treatment with enfortumab vedotin, either alone or with another immunotherapy drug.
- You agree to have regular check-ups for your nervous system during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how enfortumab vedotin, a cancer drug, affects the nerves. It aims to understand and track neuropathy (nerve damage) in people with urothelial carcinoma, so doctors can better manage side effects.
This study looks at a new treatment for advanced bladder cancer (urothelial carcinoma) using two drugs, enfortumab vedotin and pembrolizumab, which help the immune system fight cancer. The study also tests a supportive therapy called Neuridase to help prevent or reduce nerve damage (peripheral neuropathy) that can be a side effect of the cancer treatment.
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
This study looks at nerve problems (peripheral neuropathy) in people with muscle-invasive bladder cancer who receive a combination of two drugs, enfortumab vedotin and pembrolizumab, before or after surgery. The goal is to understand how these treatments affect nerves and to help manage side effects.
This trial tests a drug called enfortumab vedotin combined with radiation therapy for people with locally advanced bladder cancer that hasn't spread to distant organs. The goal is to see if this combination works better than radiation alone and helps control the cancer.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
Hear when a new Locally Advanced or Metastatic Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.